Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

A Clinical Wake Up Call: Diagnostic Strategies and Novel Therapies in Idiopathic Hypersomnia

Premiere Date: Thursday, March 31, 2022

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, March 31, 2023
Note: Credit Is No Longer Available


Michael J. Thorpy, MDMichael J. Thorpy, MD (Moderator)
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Bronx, NY
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology

Nancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNSNancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNS 
Professor of Neurology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Sleep Disorders Center
Cleveland, OH

Yves Dauvilliers, MD, PhDYves Dauvilliers, MD, PhD 
Professor of Neurology and Physiology
University of Montpellier
Director, Sleep-Wake Disorders Centre
Department of Neurology
Gui de Chauliac Hospital
Montpellier, France

Statement of Need

Idiopathic hypersomnia (IH) is a chronic, debilitating condition that includes long nocturnal sleep and/or daytime naps, unrefreshing sleep, difficulty awakening, cognitive dysfunction, and automatic symptoms. These symptoms, in turn, profoundly impact daytime functioning and quality of life (QoL). Despite IH’s incapacitating nature, diagnostic delays are rampant, further contributing its burden. Until recently, there were no FDA-approved treatments for IH; however, new clinical trial data have resulted in the first approval of a treatment for IH. It is imperative that health care providers are aware of these recent data and how it can influence the safe, effective management of IH.

This CME Outfitters' Live and OnDemand activity will feature expert faculty detailing the functional and clinical impact of IH, best practices and the latest tools for an accurate diagnosis, and the efficacy and safety of novel therapies and how they address the unmet needs of people with IH.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the QoL, functional, and clinical impact of IH to strengthen dialogues with patients.
  • Apply best practices to accurately diagnose IH.
  • Analyze the efficacy and safety of novel therapies for IH addressing the unmet needs of people with IH.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals.

Target Audience

Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in sleep medicine, pulmonology, psychiatry, neurology, and/or primary care

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring activity

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Thorpy reports the following financial relationships:
Consultant and Advisory Boards: Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma

Dr. Foldvary-Schaefer reports the following financial relationships:
Research support: Jazz Pharmaceuticals, Inc.; Suven Life Sciences Limited; and Takeda Pharmaceuticals U.S.A., Inc.
Advisory Committee: Jazz Pharmaceuticals, Inc.
Consultant: Jazz Publication Committee

Dr. Dauvilliers reports the following financial relationships:
Consultant: Avadel; Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Theranexus; and UCB S.A., Belgium

The following peer reviewer, patients, and CME Outfitters staff have no financial relationships to disclose:

  • Marlon (Tony) Graham, MD (peer reviewer)
  • Addison Horne (patient)
  • Michele Horne (patient)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download